Topical apraclonidine can also decrease IOP in glaucoma patients by increasing trabecular outflow, in a similar way to [[clonidine]],<ref>{{Cite journal | doi = 10.1016/S0161-6420(95)31000-7| title = Effects of Apraclonidine on Aqueous Humor Dynamics in Human Eyes| journal = Ophthalmology| volume = 102| issue = 3| pages = 456| year = 1995| last1 = Toris | first1 = C. B. | last2 = Tafoya | first2 = M. E. | last3 = Camras | first3 = C. B. | last4 = Yablonski | first4 = M. E. }} </ref> but without the cardiovascular side effects. Apraclonidine has been compared with other treatments such as [[brimonidine]] and [[pilocarpine]] in preventing IOP spikes after [[trabeculoplasty|laser trabeculoplasty]].<ref name="Zhang">{{cite journal | author=Zhang L, Weizer JS, Musch DC | title= Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty | journal= Cochrane Database Syst Rev | volume= | issue= 2 | pages= CD010746 | date= 2017 | pmid= 28231380 | doi= 10.1002/14651858.CD010746.pub2}}</ref> The results did not show significant differences in the reduction of IOP for apraclonidine, when compared to brimonidine or pilocarpine.<ref name="Zhang" />
